SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid concerns about the cost of capital related to a large senior secured notes offering, with community members debating its potential impact and investor appetite. Some traders speculate about an upcoming short squeeze due to the high short interest, while others discuss institutional hedging strategies involving long positions and put options. Despite recent price declines, long-term bulls cite significant AI infrastructure contracts and partnerships, urging patience and viewing the dip as a buying opportunity.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as the stock hits all-time lows, triggering strong reactions from both bulls and bears. The community is actively debating whether the stock is a buying opportunity or a value trap, with some citing upcoming earnings as a potential catalyst. Discussions also include the impact of a recent partnership and broader market conditions on the stock's performance.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential for government funding and the significance of Gerard Barron's trip to DC, alongside commentary on permit timelines. The stock's confidence-inspiring earnings call and the vessel's upcoming work in Japan are also key talking points, though some express concerns about market manipulation and the government shutdown's impact.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision from the European Medicines Agency (EMA) regarding its Alzheimer's drug, Blarcamesine; the community is split, with some anticipating approval based on the drug's potential and safety profile, while others express concern over trial data and the influence of negative opinions from figures like Martin Shkreli. Discussions also include short squeeze potential, stock manipulation accusations, and comparisons to other Alzheimer's drugs.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to concerns about reduced guidance for 2025 and disappointing earnings, leading to discussions about management credibility and the impact of government shutdowns on contracts. The community is comparing RCAT's performance to competitors like ONDS, with some expressing frustration over missed promises and potential buying opportunities at lower prices. Sentiment is mixed, with long-term bulls remaining hopeful despite recent struggles.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to recent earnings results that spurred a significant sell-off, with the community debating the company's future prospects and management's communication. Discussions revolve around the impact of facility upgrades, government shutdowns, and the strength of the Dell partnership on TSSI's performance. Some investors see this as a buying opportunity, while others express concerns about the company's execution and transparency.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending downwards following its earnings report, with concerns arising from weaker-than-expected guidance and a significant revenue impact due to new export restrictions, particularly affecting business in China. Community discussion revolves around the severity of the issues and whether the dip represents a buying opportunity or a sign of deeper challenges for the company and the semiconductor equipment sector. Some analysts highlight long-term growth potential, while others point to near-term headwinds and market share losses.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as a Bitcoin-native memecoin with a focus on community and a fair launch, contrasting it with other memecoins. Talk centers on potential exchange listings, its connection to Bitcoin's fundamentals, and the strength of its community, the #dogarmy.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending as investors await potential FDA approval for Narsoplimab (NARSO) for TA-TMA by the end of December, with specific focus on the commencement of labeling discussions, a key indicator of progress; some express concern over potential review delays and the impact of the government shutdown. The community is weighing the implications of recent leadership changes at the FDA, with opinions divided over how it might affect OMER's prospects, while also monitoring the progress of the Novo Nordisk deal and potential buy out.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings ($NU) is trending as investors react to recent earnings and growth metrics, with community members debating whether the subdued market reaction reflects the stock's true potential.  Bullish sentiment centers on the company's impressive customer growth and profitability in Latin America, while bears express concerns about sideways trading and the stock's historical difficulty in breaking resistance levels. Discussions also include potential catalysts, such as expansion into the U.S. market and partnerships with companies like Amazon and OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences (NYSE:RCUS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Arcus Biosciences (NYSE:RCUS - Get Free Report) announced its earnings results on Wednesday. The company reported ($1.27) earnings per share for the quarter, beating the consensus estimate of ($1.28...

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer...

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +4.51% and +27.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory...

Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains?

Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Taiho Pharmaceutical Co., Ltd. (Taiho) and Arcus Biosciences, Inc. (NYSE:RCUS, Arcus) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International...

Retail chatter around Arcus Biosciences picked up late Sunday after the company reported that its experimental cancer drug combination — domvanalimab and zimberelimab, given with chemotherapy — helped patients with advanced stomach and esophageal cancer live a median of 26.7 months in a mid-stage (Phase 2) study.The first overall survival results from Arm A1 of the trial will be presented on Oct. 18 at the European Society for Medical Oncology 2025 Congress, with data supporting ongoing development of the regimen in the Phase 3 STAR-221 study.According to the company’s statement, half of the patients enrolled in Arm A1 lived more than two years following treatment with domvanalimab plus zimberelimab and chemotherapy. Median progression-free survival reached 12.9 months, while confirmed objective response rate stood at 59% across all PD-L1 subgroups.&nbsp;Sun Young Rha, professor of Medical Oncology in the Department of Internal Medicine at Yonsei University College of Medicine, said the 26.7-month survival “is well beyond what would be required to demonstrate clinically meaningful benefit over standard of care.”As of March 3, the treatment demonstrated benefits across various patient groups based on PD-L1, a protein that enables tumors to evade the immune system, with approximately half of the patients still alive two years after initiating therapy. No new safety concerns were seen, and side effects were similar to what’s usually expected with immune therapy and chemotherapy.Arcus, working together with Gilead Sciences, is studying how combinations of anti-TIGIT and anti-PD-1 therapies might help people with advanced stomach and esophageal cancers.&nbsp;The ongoing Phase 3 STAR-221 trial has already enrolled over 1,000 patients around the world to see whether the domvanalimab and zimberelimab combo can perform better than current treatments using nivolumab. Both drugs are still experimental and have not yet been approved by regulators.One user said that the results showed more than a year of added survival compared with current treatments, calling it an “unprecedented” outcome for such a hard-to-treat cancer.&nbsp;<stembedurl>https://stocktwits.com/wetsalmon/message/632042158</stembedurl>Another user praised the 26-month figure as a standout result, saying it easily surpassed data from the CheckMate-649 study.<stembedurl>https://stocktwits.com/Bobes/message/632039177</stembedurl><a href="https://stocktwits.com/symbol/RCUS">Arcus Biosciences’ stock</a> has declined 2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arcus Biosciences’ stock (RCUS) has declined 2% so far in 2025. (Photo credit: Getty Images)

Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’

The company reported strong survival data from its mid-stage trial combining domvanalimab and zimberelimab with chemotherapy in advanced stomach and esophageal cancer.

Equity

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

RCUS
Arcus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RCUS News

RCUSArcus Biosciences Inc